GeneDx WGS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
GeneDx (WGS) Business Model and Operations Summary
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Key Insights
GeneDx (WGS) Core Market Data and Business Metrics
Latest Closing Price
$88.565Market Cap
$2.40 BillionPrice-Earnings Ratio
-45.65Total Outstanding Shares
28.07 Million SharesTotal Employees
1,000Dividend
No dividendIPO Date
July 23, 2021SIC Description
Services-health ServicesPrimary Exchange
NASDAQHeadquarters
333 Ludlow Street, Stamford, CT, 06902
Historical Stock Splits
If you bought 33 shares of WGS before May 4, 2023, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| May 4, 2023 | 1-for-33 (Reverse Split) |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $44.16 Million |
| Net Cash Flow From Operating Activities | $-28.50 Million |
| Net Cash Flow From Financing Activities, Continuing | $44.16 Million |
| Net Cash Flow From Operating Activities, Continuing | $-28.50 Million |
| Net Cash Flow, Continuing | $-14.47 Million |
| Net Cash Flow | $-14.47 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations After Tax | $-52.29 Million |
| Nonoperating Income/Loss | $-29.42 Million |
| Costs And Expenses | $358.08 Million |
| Gross Profit | $194.40 Million |
| Income/Loss From Continuing Operations Before Tax | $-52.63 Million |
| Income Tax Expense/Benefit | $-343,000 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $405,000 |
| Comprehensive Income/Loss Attributable To Parent | $-51.88 Million |
| Comprehensive Income/Loss | $-51.88 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Non-current Assets | $29.92 Million |
| Prepaid Expenses | $7.42 Million |
| Current Liabilities | $54.82 Million |
| Intangible Assets | $158.60 Million |
| Other Current Liabilities | $46.86 Million |
| Noncurrent Assets | $221.41 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||